Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Aug 26

PMID 36012987

Authors

Merce Giner

Maria Angeles Vazquez-Gamez

Maria Jose Miranda

Jesus Bocio-Nunez

Francisco Jesus Olmo-Montes

Miguel Angel Rico

Miguel Angel Colmenero

Maria-Jose Montoya-Garcia

Affiliations

Soon will be listed here.

Abstract

Circulating osteogenic precursor (COP) cells are peripheral blood cells with a capacity for osteogenesis. The objective of our study was to ascertain the percentage of COPs as an early biomarker of osteoporosis and the effect of these cells in response to Denosumab (DmAb) (anti-resorptive) or to Teriparatide (TPDP) (anabolic) as very effective drugs in the treatment of the illness. A first study was conducted on healthy volunteers, with three age ranges, to determine the percentage of COPs and relate it to their anthropometric and biochemical characteristics, followed by a second longitudinal study on patients with osteoporosis, whereby one group of patients was treated with TPTD and another with DmAb. All were analyzed by cytometry for COP percentage in blood, bone turnover markers, and bone mass. Our findings show that COPs are influenced by age and become more prolific in the stages of growth and skeletal maturation. A higher percentage of COPs is found in osteoporotic disease, which could constitute a predictive marker thereof. We also show how treatment with TPTD or DmAb mobilizes circulating osteogenic precursors in the blood. Significant increases in % COPs were observed after 12 months of treatment with Dmb (21.9%) and TPTD (17%). These results can be related to an increase in osteogenesis and, consequently, a better and more efficient repair of bone tissue.

References

Ritz U, Spies V, Mehling I, Gruszka D, Rommens P, Hofmann A . Mobilization of CD34+-progenitor cells in patients with severe trauma. PLoS One. 2014; 9(5):e97369. PMC: 4020858. DOI: 10.1371/journal.pone.0097369. View

Kumagai K, Vasanji A, Drazba J, Butler R, Muschler G . Circulating cells with osteogenic potential are physiologically mobilized into the fracture healing site in the parabiotic mice model. J Orthop Res. 2007; 26(2):165-75. DOI: 10.1002/jor.20477. View

Gunawardene P, Al Saedi A, Singh L, Bermeo S, Vogrin S, Phu S . Age, gender, and percentage of circulating osteoprogenitor (COP) cells: The COP Study. Exp Gerontol. 2017; 96:68-72. DOI: 10.1016/j.exger.2017.06.004. View

Pasqualini L, Ministrini S, Lombardini R, Bagaglia F, Paltriccia R, Pippi R . Effects of a 3-month weight-bearing and resistance exercise training on circulating osteogenic cells and bone formation markers in postmenopausal women with low bone mass. Osteoporos Int. 2019; 30(4):797-806. DOI: 10.1007/s00198-019-04908-9. View

Garnero P . The Utility of Biomarkers in Osteoporosis Management. Mol Diagn Ther. 2017; 21(4):401-418. DOI: 10.1007/s40291-017-0272-1. View

Feehan J, Smith C, Tripodi N, Degabrielle E, Al Saedi A, Vogrin S . Higher Levels of Circulating Osteoprogenitor Cells Are Associated With Higher Bone Mineral Density and Lean Mass in Older Adults: A Cross-Sectional Study. JBMR Plus. 2021; 5(11):e10561. PMC: 8567483. DOI: 10.1002/jbm4.10561. View

Lyu H, Zhao S, Yoshida K, Tedeschi S, Xu C, Nigwekar S . Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use. J Clin Endocrinol Metab. 2019; 104(11):5611-5620. PMC: 6785688. DOI: 10.1210/jc.2019-00924. View

Alm J, Koivu H, Heino T, Hentunen T, Laitinen S, Aro H . Circulating plastic adherent mesenchymal stem cells in aged hip fracture patients. J Orthop Res. 2010; 28(12):1634-42. DOI: 10.1002/jor.21167. View

Tabacco G, Bilezikian J . Osteoanabolic and dual action drugs. Br J Clin Pharmacol. 2018; 85(6):1084-1094. PMC: 6533433. DOI: 10.1111/bcp.13766. View

10.

Langdahl B . Overview of treatment approaches to osteoporosis. Br J Pharmacol. 2020; 178(9):1891-1906. DOI: 10.1111/bph.15024. View

11.

Al Saedi A, Phu S, Vogrin S, Gunawardene P, Duque G . Association between Circulating Osteoprogenitor Cells and Sarcopenia. Gerontology. 2021; 68(9):1038-1043. DOI: 10.1159/000520488. View

12.

Dalle Carbonare L, Valenti M, Zanatta M, Donatelli L, Lo Cascio V . Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. Arthritis Rheum. 2009; 60(11):3356-65. DOI: 10.1002/art.24884. View

13.

Feehan J, Kassem M, Pignolo R, Duque G . Bone From Blood: Characteristics and Clinical Implications of Circulating Osteogenic Progenitor (COP) Cells. J Bone Miner Res. 2020; 36(1):12-23. DOI: 10.1002/jbmr.4204. View

14.

Yu E, Kumbhani R, Siwila-Sackman E, DeLelys M, Preffer F, Leder B . Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women. J Bone Miner Res. 2014; 29(6):1380-6. PMC: 4564394. DOI: 10.1002/jbmr.2171. View

15.

Albiero M, Bonora B, Fadini G . Diabetes pharmacotherapy and circulating stem/progenitor cells. State of the art and evidence gaps. Curr Opin Pharmacol. 2020; 55:151-156. DOI: 10.1016/j.coph.2020.10.019. View

16.

Kelly R, McDonald L, Pellegrini V, Cray J, LaRue A . Identification of circulating murine CD34OCN cells. Cytotherapy. 2018; 20(11):1371-1380. DOI: 10.1016/j.jcyt.2018.07.004. View

17.

Tang Y, Xia H, Kang L, Sun Q, Su Z, Hao C . Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women. Med Sci Monit. 2019; 25:259-268. PMC: 6330838. DOI: 10.12659/MSM.913752. View

18.

DAmelio P, Cristofaro M, Grimaldi A, Ravazzoli M, Pluviano F, Grosso E . The role of circulating bone cell precursors in fracture healing. Calcif Tissue Int. 2010; 86(6):463-9. DOI: 10.1007/s00223-010-9362-3. View

19.

Bone H, Wagman R, Brandi M, Brown J, Chapurlat R, Cummings S . 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5(7):513-523. DOI: 10.1016/S2213-8587(17)30138-9. View

20.

Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View